Sotatercept as an alternative therapeutic strategy in high-risk pulmonary hypertension associated with systemic sclerosis and interstitial lung disease when prostacyclin therapy is not feasible

29 August 2026 (17:30 - 17:44)
Organised by: Logo
Congress Presentation Part of: Pulmonary hypertension in the real world Clinical ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology